Clinical effectiveness of tumor markers in squamous cell carcinoma of the larynx

Anticancer Research

Volumn 26, Issue 3 B, 2006, Pages 2493-2497

  Eleftheriadou, Anna ^a,d   Chalastras, Thomas ^a   Ferekidou, Elisa ^c   Kyriou, Lambrini ^b   Yiotakis, Ioannis ^c   Pappas, Zisis ^a   Ferekidis, Eleftherios ^c   Kandiloros, Dimitrios ^c  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d NONE   (Greece)

Author keywords

CEA; CYFRA 21 1; SCC of the larynx; SCCA; TPA M; Tumor markers

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; SQUAMOUS CELL CARCINOMA ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CANCER GRADING; CANCER STAGING; CELL DIFFERENTIATION; COHORT ANALYSIS; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; FEMALE; HUMANS; KERATINS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SERPINS; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 33745578609     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Dietz A: Epidemiology of laryngeal cancer. Laryngorhinootologie 83(11): 771-772, 2004.
2. Fujieda S: Prognostic factors for head and neck cancer. Gan To Kagaku Ryoho 28 (Review Japanese (4)): 440-447, 2001.
3. Paparella M and Shumrick D: Otolaryngology. Third edition, Vol. III, 1991.
4. Rassekh C, Johnson J and Eibling E: Circulating markers in squamous cell carcinoma of the head and neck: a review. Oral Oncol Eur J Cancer 30B: 23-28, 1994.
5. Straka M, Wagner R, Johnson J, Kachman K and Eibling D: The lack of utility of a tumour marker panel in head and neck carcinoma. Arch Otolaryng Head Neck Surg 118: 802-805, 1992.
6. Ho S, Leung WT, Yuen J and Jonhson PJ: Serum levels of CYFRA 21-1 in nasopharyngeal carcinoma and its possible role in monitoring of therapy. Oral Oncol Eur J Cancer 32B(6): 377-380, 1996.
7. Molina R, Torres MD, Moragas M, Filella X, Jo J, Gimenez N, Traserra J and Ballesta A: Prognostic value of TPS in patients with head and neck malignancies: comparison with SCC. Anticancer Res 15: 479-484, 1995.
8. Tannapfel A and Weber A: Tumor markers in squamous cell carcinoma of the head and neck: clinical effectiveness and prognostic value. Eur Arch Otorhinolayngol 258: 83-88, 2001.
9. Becciolini A, Porciani S, Lanini A, Tommasi M, Olmi P and Chiavacci A: Prognostic significance of tissue polypeptide antigen (TPA) in head and neck carcinomas. Acta Otolaryngol 32(3): 295-299, 1993.
10. Kuo WR, Tsai SM, Jong SB and Juan KH: Significance of tumour markers in nasopharyngeal carcinoma. J Otolaryngol 25(1): 32-36, 1996.
11. Tai CJ, Liu FY, Liang JA, Yang SN, Tsai MH and Kao CH: Comparison of Cyfra 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma. Anticancer Res 22: 3793-3796, 2002.
12. Maass JD, Niemann AM, Lippert BM, Gottschlich S, Folz BJ and Werner JA: CYFRA 8/18 in head and neck cancer. Anticancer Res 19: 2699-2702, 1999.
13. Banal A, Hacene K, Berthelot-Ruff E, Mahe E, Fontana X and Pichon MF: Comparison of Cyfra 21-1 and SCC assays in head and neck tumours. Tumour-Biol 22(1): 27-35, 2001.
14. Niemann AM, Goeroegh T, Gottschlich S, Lippert BM and Werner JA: Cut off value determination of CYFRA 21-1 for squamous cell carcinomas of the head and neck (SCCHN). Anticancer Res 17: 2859-2860, 1997.
15. Nagler RM, Barak M, Peled M, Ben-Aryeh H, Filatof M and Laufer D: Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma. Cancer/Radiother 85(5): 1018-1025, 1999.
16. Pradier O, Hille A, Schmiberger H and Hess CF: Monitoring of therapy in head and neck patients during the radiotherapy by measurement of Cyfra 21-1. Cancer/Radiother 6: 15-21, 2002.
17. Kulpa J, Stasik Z, Skolyszewski J, Wojcik E, Rychlik U and Pudelek K: Predictive value of SCC-Ag, CYFRA 21-1 and selected acute phase proteins in radiotherapy of pharyngeal and laryngeal cancer. A preliminary report. Neoplasma 51(2): 103-109, 2004.
18. Deng YF, Chen PC, Lin YZ, Le JZ, Wu XL, Yu MQ, Zhuang PY and Gao MH: Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma. J Laryngol Otol 117: 190-194, 2003.
19. Bongers V, Braakhuis JM and Snow GB: Circulating fragments of cytokeratin 19 in patients with head and neck squamous cell carcinoma. Clin Otolaryngol 20: 479-482, 1995.
20. Ogawa T, Tsurusako U, Kimura N, Nishioka S, Akagi H, Nishizaki K, Nishioka K and Rutka J: Comparison of tumor markers in patients with squamous cell carcinoma of the head and neck. Acta Otolaryngol (Stockh) Suppl (540): 72-76, 1999.
21. Doweck I, Barak M, Greenberg E, Uri N, Kellner J and Lurie M: Cyfra 21-1. A new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryng Head Neck Surg 121: 177-181, 1995.
22. Hamakawa H, Bao Y, Takarada M, Fukuzumi M and Tanioka H: Cytokeratin expression in squamous cell carcinoma of the lung and oral cavity. An immunohistochemical study with possible clinical relevance. Oral Surg Oral Med Oral Pathol 85(4): 438-443, 1998.
23. Kuropkat C, Lippert BM and Werner JA: Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinoma of the head and neck. Ongology 63: 280-285, 2002.
24. Nap M, Van Wek T, Andres C and Bellanger L: Immunohistochemical profiles of 30 monoclonal antibodies against cytokeratin 8,18 and 19. Tumor Biol 22: 4-10, 2001.
25. Lin WY, Yen TC, Cheng KY and Wang SJ: The value of Cyfra 21-1, a new tumor marker, in nasopharyngeal carcinoma. Neoplasma 45(1): 21-24, 1998.
26. Lee JK, Hsieh JF, Tsai SC, Ho YJ, Sun SS and Kao CH: Comparison of Cyfra 21-1 and squamous cell carcinoma antigen in detecting nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol 110(8): 775-778, 2001.
27. Yen TC, Lin WY, Kao CH, Cheng KY and Wang SJ: A study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Clin Otolaryngol 23: 82-86, 1998.